^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
valacyclovir
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Generic mfg.
Drug class:
DNA polymerase inhibitor
Related drugs:
1d
Ultrasound-Guided Thoracic Paravertebral Block With Steroid and Local Anesthetic for Acute Herpes Zoster: Effects on Pain Control and Prevention of Postherpetic Neuralgia (clinicaltrials.gov)
P3, N=100, Completed, Assiut University
New P3 trial
|
valacyclovir
6d
ADePT: Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma (clinicaltrials.gov)
P1/2, N=68, Not yet recruiting, Trogenix ltd
New P1/2 trial
|
valacyclovir
10d
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec (clinicaltrials.gov)
P2, N=30, Recruiting, Candel Therapeutics, Inc.
New P2 trial
|
ProstAtak (aglatimagene besadenovec) • valacyclovir
1m
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study (clinicaltrials.gov)
P=N/A, N=80, Recruiting, National Taiwan University Hospital
New trial • Head-to-Head
|
Valcyte (valganciclovir) • valacyclovir
3ms
Neonatal Phase 1 Valacyclovir Study (clinicaltrials.gov)
P1, N=17, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed
Trial completion
|
valacyclovir
5ms
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors (clinicaltrials.gov)
P1, N=11, Not yet recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Aug 2030 --> Nov 2030 | Initiation date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2030 --> Nov 2030
Trial completion date • Trial initiation date • Trial primary completion date
|
valacyclovir
5ms
Neonatal Phase 1 Valacyclovir Study (clinicaltrials.gov)
P1, N=17, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting
Enrollment closed
|
valacyclovir
6ms
Clinical Observation on the Treatment of herpes zoster with "specimen and acupoint combination" acupuncture (ChiCTR2500106201)
P=N/A, N=64, Not yet recruiting, Hubei Provincial Hospital of Traditional Chinese Medicine; Hubei Provincial Hospital of Traditional Chinese Medicine
New trial
|
valacyclovir
6ms
PrTK03: Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer (clinicaltrials.gov)
P3, N=711, Active, not recruiting, Candel Therapeutics, Inc. | Trial completion date: Dec 2024 --> Dec 2030 | Trial primary completion date: Dec 2024 --> Aug 2024
Trial completion date • Trial primary completion date
|
ProstAtak (aglatimagene besadenovec) • valacyclovir
7ms
Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=12, Completed, Candel Therapeutics, Inc. | Active, not recruiting --> Completed
Trial completion
|
ProstAtak (aglatimagene besadenovec) • valacyclovir
7ms
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) (clinicaltrials.gov)
P2, N=187, Active, not recruiting, Candel Therapeutics, Inc.
Trial completion date
|
ProstAtak (aglatimagene besadenovec) • valacyclovir
8ms
Effect of Valaciclovir on Inter-Appointment Pain in Endodontic Treatment of Necrotic Teeth (clinicaltrials.gov)
P=N/A, N=38, Completed, Tehran University of Medical Sciences
New trial
|
valacyclovir
Share via
